Document 0013
 DOCN  M9470013
 TI    Combined daily therapy with intravenous ganciclovir and foscarnet for
       patients with recurrent cytomegalovirus retinitis.
 DT    9409
 AU    Weinberg DV; Murphy R; Naughton K; Department of Ophthalmology,
       Northwestern University Medical; School, Chicago, Illinois.
 SO    Am J Ophthalmol. 1994 Jun 15;117(6):776-82. Unique Identifier : AIDSLINE
       MED/94256533
 AB    We treated seven patients (nine eyes) who had cytomegalovirus retinitis
       with daily intravenous ganciclovir plus foscarnet. All patients had
       demonstrated multiple progressions of retinitis on single-drug therapy,
       and some were intolerant to induction doses of one or both medications.
       Before combination therapy, the median number of progressions was five
       per patient. The mean interval between progressions was 11 weeks, and
       the mean interval before the final progression was four weeks. While
       taking combination therapy, two patients showed progression after 14 and
       34 weeks. Two patients showed no progression after 17 and 36 weeks of
       follow-up. Three patients died after five, 14, and 23 weeks,
       respectively, without progression of retinitis. In every patient, the
       progression-free interval was longer during combination therapy than the
       previous progression-free interval during single-drug therapy. In no
       case was combination therapy stopped because of toxicity. Combination
       therapy was fairly well tolerated and appeared to prolong the interval
       to progression and to preserve vision in our patients.
 DE    Adult  AIDS-Related Opportunistic Infections/*DRUG THERAPY  Case Report
       Comparative Study  Cytomegalovirus Retinitis/*DRUG THERAPY  Drug
       Administration Schedule  Drug Therapy, Combination  Follow-Up Studies
       Foscarnet/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE
       Ganciclovir/*ADMINISTRATION & DOSAGE/THERAPEUTIC USE  Human  Injections,
       Intravenous  Male  Prognosis  Recurrence  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).